Valeant's dose of reality
FT News in Focus - Un podcast de Financial Times
Catégories:
Valeant was once considered a runaway success story, and one that upended the pharmaceutical sector. A series of crises engulfed the company in recent months, slashing nearly two thirds off its market valuation and forcing the company to tear up its forecasts for 2016. Correspondent David Crow explains. Read the full story at ft.com/valeant.Music: "Brand New Record!" by Steve Combs Hosted on Acast. See acast.com/privacy for more information.